Statin Use after colorectal cancer diagnosis and survival: A population-based cohort study

Journal of Clinical Oncology

Volumn 32, Issue 28, 2014, Pages 3177-3183

  Cardwell, Chris R ^a   Hicks, Blanaid M ^a   Hughes, Carmel ^a   Murray, Liam J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SURVIVAL; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RISK REDUCTION; CANCER STAGING; COLORECTAL NEOPLASMS; EPIDEMIOLOGY; HEALTH SURVEY; MIDDLE AGED; MORTALITY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; REGISTER; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TIME; TRENDS; UNITED KINGDOM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; GREAT BRITAIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NEOPLASM STAGING; POPULATION SURVEILLANCE; PROPORTIONAL HAZARDS MODELS; REGISTRIES; SURVIVAL RATE; TIME FACTORS;

EID: 84907478534     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.4569     Document Type: Article

References (34)

1. Boudreau DM, Yu O, Johnson J: Statin use and cancer risk: A comprehensive review. Expert Opin Drug Saf 9:603-621, 2010
2. Gauthaman K, Fong CY, Bongso A: Statins, stem cells, and cancer. J Cell Biochem 106:975-983, 2009
3. Chan KK, Oza AM, Siu LL: The statins as anticancer agents. Clin Cancer Res 9:10-19, 2003
4. Ahern TP, Pedersen L, Tarp M, et al: Statin prescriptions and breast cancer recurrence risk: A Danish nationwide prospective cohort study. J Natl Cancer Inst 103:1461-1468, 2011
5. Yu O, Eberg M, Benayoun S, et al: Use of statins and the risk of death in patients with prostate cancer. J Clin Oncol 32:5-11, 2014
6. Kumar AS, Campbell M, Benz CC, et al: A call for clinical trials: Lipophilic statins may prove effective in treatment and prevention of particular breast cancer subtypes. J Clin Oncol 24:2127-2128, 2006
7. Narisawa T, Morotomi M, Fukaura Y, et al: Chemoprevention by pravastatin, a 3-hydroxy-3- methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats. Jpn J Cancer Res 87:798-804, 1996
8. Kodach LL, Bleuming SA, Peppelenbosch MP, et al: The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway. Gastroenterology 133:1272-1281, 2007
9. Lakha F, Theodoratou E, Farrington SM, et al: Statin use and association with colorectal cancer survival and risk: Case control study with prescription data linkage. BMC Cancer 12:487, 2012
10. Mace AG, Gantt GA, Skacel M, et al: Statin therapy is associated with improved pathologic response to neoadjuvant chemoradiation in rectal cancer. Dis Colon Rectum 56:1217-1227, 2013
11. Ng K, Ogino S, Meyerhardt JA, et al: Relationship between statin use and colon cancer recurrence and survival: Results from CALGB 89803. J Natl Cancer Inst 103:1540-1551, 2011
12. Jick H, Jick SS, Derby LE: Validation of information recorded on general practitioner based computerized data resource in the United Kingdom. BMJ 302:766-768, 1991
13. Booth-Clibborn N, Packer C, Stevens A: Health technology diffusion rates: Statins, coronary stents, and MRI in England. Int J Technol Assess Health Care 16:781-786, 2000
14. British Medical Association and the Royal Pharmaceutical Society of Great Britain: British National Formulary.
15. World Health Organization: World Health Organization Collaborating Centre for Drug Statistics Methodology.
16. Levesque LE, Hanley JA, Kezouh A, et al: Problem of immortal time bias in cohort studies: Example using statins for preventing progression of diabetes. BMJ 340:b5087, 2010
17. Chubak J, Boudreau DM, Wirtz HS, et al: Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival. J Natl Cancer Inst 105:1456-1462, 2013
18. Khan NF, Perera R, Harper S, et al: Adaptation and validation of the Charlson Index for Read/ OXMIS coded databases. BMC Fam Pract 11:1, 2010
19. Noble M, Wright G, Dibben C, et al: Indices of deprivation 2004: Report to the office of the deputy prime minister. London, UK, Neighbourhood Renewal Unit, 2004
20. Zhou Z, Rahme E, Abrahamowicz M, et al: Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: A comparison of methods. Am J Epidemiol 162:1016-1023, 2005
21. Leuven E, Sianesi B: PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing: Version 4.0.5.
22. Austin PC: Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 10:150-161, 2011
23. Austin PC: The performance of different propensity score methods for estimating marginal hazard ratios. Stat Med 32:2837-2849, 2013
24. Weinberg CR: Toward a clearer definition of confounding. Am J Epidemiol 137:1-8, 1993
25. Schisterman EF, Cole SR, Platt RW: Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology 20:488-495, 2009
26. Logan RF, Patnick J, Nickerson C, et al: Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests. Gut 61:1439-1446, 2012
27. Nielsen SF, Nordestgaard BG, Bojesen SE: Statin use and reduced cancer-related mortality. N Engl J Med 367:1792-1802, 2012
28. Siddiqui AA, Nazario H, Mahgoub A, et al: For patients with colorectal cancer, the long-term use of statins is associated with better clinical outcomes. Dig Dis Sci 54:1307-1311, 2009
29. United States National Institutes of Health: Study record detail: Statin polyp prevention trial in patients with resected colon cancer.
30. Stewart D, Cunningham IT, Hansford D, et al: General practitioners' views and experiences of over-the-counter simvastatin in Scotland. Br J Clin Pharmacol 70:356-359, 2010
31. Yood MU, Campbell UB, Rothman KJ, et al: Using prescription claims data for drugs available over-the-counter (OTC). Pharmacoepidemiol Drug Saf 16:961-968, 2007
32. Clancy Z, Keith SW, Rabinowitz C, et al: Statins and colorectal cancer risk: A longitudinal study. Cancer Causes Control 24:777-782, 2013
33. Bosco JL, Silliman RA, Thwin SS, et al: A most stubborn bias: No adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol 63:64-74, 2010
34. Shrank WH, Patrick AR, Brookhart MA: Healthy user and related biases in observational studies of preventive interventions: A primer for physicians. J Gen Intern Med 26:546-550, 2011.